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How to Measure Endothelial Function
Several methods to measure endothelial function in vivo are cur−
rently known. It should be noted that there is no direct measure−
ment of endothelial function available in humans. The tech−
niques described below provide reasonable but imperfect esti−
mates of endothelial function in humans. Since 1986, direct
measurement of coronary artery relaxation after acetylcholine
infusions has been used to assess endothelial function in patients
with coronary artery disease [1]. However, the invasive nature of
this technique means that it is not a suitable method for measur−
ing endothelial function in other patient groups.
Another technique for measuring endothelial function is strain−
gauge plethysmography. The response of the forearm vascular
bed to infusion of vasodilator or vasoconstrictive agents is deter−
mined by direct infusion of these agents into the brachial artery.
However, this method is time−consuming and invasive, and
therefore not suitable for usage in large populations.
In 1992, a new non−invasive flow−mediated vasodilation tech−
nique was introduced by Celermajer et al. [2] This technique has
now been used by numerous groups worldwide. The Internation−
al Brachial Artery Reactivity Task Force has extensively described
the technique’s methods, along with the technical and interpre−
tive limitations to this technique [3].
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Abstract
Over the last two decades, it has become evident that the endo−
thelium is more than an inert, single−cell lining covering the in−
ternal surface of blood vessels. Normally, the endothelium ac−
tively decreases vascular tone, maintains vascular permeability
within narrow bounds, inhibits platelet adhesion and aggrega−
tion, limits activation of the coagulation system, and stimulates
fibrinolysis. Endothelium dysfunction can be considered present
when its functions, either in the basal state or after stimulation,
are altered in a way that is inappropriate to the preservation of
organ function. Endothelial dysfunction has been associated to
many cardiovascular risk factors including diabetes, hyperten−
sion and hypercholesterolemia. In addition, endothelial dysfunc−
tion may play a crucial role in the development and progression
of atherosclerosis. This review will give a brief overview of the
different methods to assess endothelial function, and then will
focus on the current knowledge on soluble cellular adhesion
molecules in relation to the metabolic syndrome and type 2 dia−
betes.
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Endothelial function can also be measured using plasma levels of
markers of endothelial function such as von Willebrand factor
and soluble cellular adhesion molecules. Like other techniques,
this concept is based on several assumptions ± first, that cell
types other than endothelial cells are not an important source
of these markers. Second, that synthesis is more important than
clearance. Third, that endothelial function in the microcircula−
tory parallels that in large arteries since microvascular endothe−
lium has a very large surface area and synthetic capacity, and
may therefore be the most important source of these endothelial
markers. Information on the validity of these assumptions is
scarce. However, plasma levels of soluble cell adhesion mol−
ecules are easy to determine in large populations. These meas−
urements are relatively independent of observer variability and
less time−consuming than other techniques.
Endothelial Cell Adhesion Molecules
Cellular adhesion molecules mediate the attachment and trans−
migration of leukocytes across the endothelial surface in re−
sponse to several inflammatory cytokines (Fig.1), and are hypo−
thesized to play an important role in the initiation of athero−
sclerosis [4]. Three groups of cellular adhesion molecules have
been described: integrins, selectins, and members of the immu−
noglobulin family. The focus of this review will be on the latter
two.
Several selectins have been found on the endothelium ± L−selec−
tin, P−selectin, and E−selectin. The latter is exclusively found on
the surface of stimulated endothelial cells. This specificity pro−
vides an opportunity for studying the pathophysiological aspects
of endothelial function. E−selectin binds neutrophils, monocytes,
eosinophils, basophils, natural killer (NK) cells, and subsets of
lymphocytes. This adhesion molecule has been shown to be im−
portant in the initial steps of leukocyte extravasation into in−
flamed tissues [5]. Levels of soluble E−selectin (sE−selectin) in
plasma correlate to its membrane−bound expression [6].
Vascular cell adhesion molecule−1 (VCAM−1) is a membrane−
bound adhesion molecule receptor and a member of the immu−
noglobulin family. VCAM−1 is thought to be a ligand for leuko−
cyte integrins that allow tethering and rolling of monocytes and
lymphocytes as well as firm attachment and transendothelial
migration of leukocytes. The membrane−bound protein is nor−
mally expressed at low levels by endothelial cells, smooth mus−
cle cells, tissue macrophages, lymphoid dendritic cells and renal
tubular cells. Soluble forms of VCAM−1 (sVCAM−1) are detectable
in plasma, and are reported to parallel the expression of the
membrane−bound form on endothelial cells [7]. Several stimuli,
including cytokines, modified lipoproteins, advanced glycation
end−products, increased blood pressure, and oxidants, can upre−
gulate VCAM−1 expression.
Intercellular adhesion molecule−1 (ICAM−1), also a member of
the immunoglobulin family, is a membrane−bound adhesion
molecule receptor for monocytes, lymphocytes and neutrophils,
and functions as a receptor for soluble fibrinogen. ICAM−1 is
expressed by endothelial cells, smooth−muscle cells and mono−
cytes. Like sE−selectin and sVCAM−1 levels, soluble ICAM−1 (sI−
CAM−1) levels are detectable in plasma, and these levels are di−
rectly associated with membrane−bound protein expression [6].
ICAM−1 levels can be upregulated by inflammatory cytokines,
but can also increase after exposure to high glucose levels. Accu−
mulating data imply that selectins mediate initial rolling of leu−
kocytes along the endothelium, and that VCAM−1 and ICAM−1
play important roles in the firm attachment and transendothelial
migration of leukocytes.
Associations Between Cellular Adhesion Molecules and
Characteristics of the Metabolic Syndrome
Type 2 diabetes is often accompanied by cardiovascular risk fac−
tors such as hypertension, obesity, dyslipidemia, and insulin re−
sistance. The combined presence of these risk factors is referred
to as the metabolic syndrome. Many variables included in the
metabolic syndrome are associated with endothelial dysfunc−
tion. The following section will discuss the associations between
endothelial cell adhesion molecules and characteristics of the
metabolic syndrome.
Hypertension
High blood pressure increases shear stress on the endothelium,
and may result in endothelial cell activation or even damage.
Several studies have reported increased levels of sVCAM−1,
sICAM−1 and sE−selectin in the presence of hypertension, al−
though conflicting results exist. Some studies only investigated
sE−selectin in hypertensive individuals, and found increased lev−
els compared to normotensive individuals [8, 9], while others
demonstrated elevated sVCAM−1 and/or sICAM−1 levels but no
increase in sE−selectin levels in hypertensive individuals [10±
12]. Two studies found elevations in all three soluble cellular ad−
hesion molecules in hypertensive individuals [13,14]. In addi−
tion, a transient elevation of sVCAM−1, sICAM−1 and sE−selectin
after a cold−pressor test has been reported in both normotensive
and hypertensive individuals [14]. Others investigated the effects
of obesity and hypertension, reporting that hypertensive and
normotensive obese men showed elevated levels of sVCAM−1,
sICAM−1 and sE−selectin [15]. However, these levels were
Fig. 1 Leukocyte−endothelial cell interactions during the initial steps
of leukocyte migration, and the role of the various adhesion molecules
in this process (Reprinted with permission from Blankenberg S et al.
Atherosclerosis 170: 191 ± 203, 2003).

































unrelated to the presence of hypertension, suggesting that the
changes in endothelial function were secondary to obesity rather
than high blood pressure.
The main problem in the above studies was the relatively small
number of individuals included; none of these studies included
more than 45 hypertensive individuals. This may, to some extent,
explain the conflicting results that have been reported, and some
of these may be due to chance. In that respect, larger studies may
provide more consistent information. The ARIC study showed
significantly elevated levels of sE−selectin in hypertension, while
levels of sVCAM−1 and sICAM−1 were similar in hypertensive and
normotensive individuals [16]. However, these results were
based on a selection of the original population of about 792 indi−
viduals based on the presence or absence of coronary heart dis−
ease, and therefore do not represent these relationships in the
general population. The Physicians’ Health Study investigated
the association of sICAM−1 levels with measures of blood pres−
sure in a large sample of middle−aged men (n = 948), and showed
a strong positive association of sICAM−1 levels with both systolic
and diastolic blood pressure [17].
Some reports dealt with specific issues that are important in hy−
pertension. Kuroda et al. [18] showed that sVCAM−1 is a marker
of left ventricular hypertrophy in hypertensive individuals, while
levels of sICAM−1 and sE−selectin were not. In addition, levels of
sE−selectin were shown to be elevated in salt−sensitive compared
to salt−resistant hypertensive individuals, while sVCAM−1 and
sICAM−1 levels were similar between the groups [19]. These two
studies included somewhat more individuals in their analyses;
however, the numbers still did not exceed a hundred, and the re−
sults were not confirmed by others.
Taken together, we can conclude that results among reports re−
main conflicting. However, all studies described above showed
an increase in at least one of the three cellular adhesion mol−
ecules. This seems to imply that increased hemodynamic stress
on the endothelium caused by hypertension might raise the ex−
pression of endothelial cell adhesion molecules. However, the re−
verse may also be true ± increased expression of endothelial cell
adhesion molecules may contribute to the development of hy−
pertension due to failure of the endothelium to perform its tasks
correctly in regulating vascular tone.
Obesity
Several studies have investigated the association of obesity with
soluble cellular adhesion molecules. Adipose tissue is thought to
be able to produce inflammatory markers such as interleukin−6
and tumor necrosis factor a (TNF−a), which in turn are able to
stimulate the expression of cellular adhesion molecules. Higher
levels of sE−selectin in obesity have been described in both men
[16] and women [20], including positive correlations with body
mass index or body fat [21 ± 23]. Conflicting results exist for the
relation of sVCAM−1 and sICAM−1 levels with obesity. Some re−
ports have shown an association between both sVCAM−1 and
sICAM−1 on the one hand, and body mass index on the other
[15,17, 24,25], while others have not [16,26]. However, the latter
included a subgroup of the ARIC study with cardiovascular dis−
ease [16] and a population of women with polycystic ovary syn−
drome [26], and may not pertain to the general population. The
degree of obesity in the individuals included may of course have
an effect on the results of the study. One study investigated
sICAM−1 levels in morbid obesity (body mass index above
35 kg/m2), and showed elevated sICAM−1 levels compared to
non−obese individuals [27].
When obesity is accompanied by type 2 diabetes, levels of sE−se−
lectin and, in most cases, sICAM−1 are associated with measures
of obesity [22, 23,28, 29]. Soluble VCAM−1 appears to be asso−
ciated with obesity in type 2 diabetic Pima Indians [23], while
no such association has been found in Caucasian and Japanese
individuals [22, 28,29]. Another study on non−diabetic Pima In−
dians demonstrated an association between sICAM−1 and per−
centage of total body fat, but not sE−selectin levels [21].
Studies on the effects of weight loss on these molecules strongly
suggest that obesity is causally involved in elevated levels of en−
dothelial cell adhesion molecules. Levels of all three endothelial
cell adhesion molecules have been reported to decrease after
weight loss [15,20, 27].
Taken together, the evidence suggests that there is indeed an as−
sociation between obesity and the expression of cellular adhe−
sion molecules. This suggests that obesity is involved in the de−
velopment of endothelial dysfunction. Studies on the effects of
weight loss suggest endothelial dysfunction caused by obesity is
reversible. Mechanisms that may explain these relationships in−
clude increased stress to the cardiovascular system in over−
weight patients, increased production of inflammatory markers
by adipocytes, or metabolic stimulus such as the effect of insulin
on the endothelium.
Dyslipidemia
Hypercholesterolemia (although not a consistent feature of the
metabolic syndrome) [30 ± 32] has been associated with elevated
levels of sVCAM−1, sICAM−1 and sE−selectin. However, in accord−
ance with the previous features of the metabolic syndrome, con−
flicting results have been published with regard to endothelial
cell adhesion molecules and dyslipidemia. No differences in
sVCAM−1 levels have been reported for hypercholesterolemia
[33± 36], while levels both elevated [33,37, 38] and comparable
to controls have been reported for sICAM−1 and sE−selectin
[34± 36,39]. Two reports on hypertriglyceridemia have demon−
strated elevated levels of all three endothelial cell adhesion mol−
ecules [33,40]. Only one study reported increased sICAM−1 levels
in familial hypercholesterolemia (FH) [41], while others showed
no differences in sVCAM−1, sICAM−1 or sE−selectin levels be−
tween FH and non−FH and control subjects [36, 42]. Calabresi et
al. [43] specifically investigated the association between low
HDL cholesterol and endothelial cell adhesion molecules, and
found significant inverse associations of HDL cholesterol and
sICAM−1 with sE−selectin, but not with sVCAM−1. However, since
only one study has reported this finding, this observation needs
to be confirmed.
Taken together, these findings suggest that dyslipidemia does
have an effect on cellular adhesion molecule levels. Hypercholes−
terolemia may have a more specific effect on sICAM−1 and sE−se−
lectin levels, whereas triglycerides and HDL cholesterol levels
would also affect sVCAM−1 levels. It seems likely that changes

































in lipid profile do have some effect on the expression of endothe−
lial cell adhesion molecules.
Insulin Resistance
Several studies have investigated the association of endothelial
cell adhesion molecules with insulin resistance in non−diabetic
individuals. These studies showed that levels of sVCAM−1, sI−
CAM−1 and sE−selectin were significantly elevated in insulin−re−
sistant individuals [21, 44 ± 47], although not all studies demon−
strated this for sVCAM−1 [21, 46]. One study investigated this is−
sue in Japanese individuals, and demonstrated increased sE−se−
lectin levels in the insulin−resistant state, while no difference in
sVCAM−1 or sICAM−1 levels was found [47].
In Caucasians, some population−based sample studies have in−
vestigated the association between insulin resistance and cellu−
lar adhesion molecules. Hak et al [46]. investigated a large group
of non−diabetic individuals from the Rotterdam study, and found
an association of sICAM−1 with post−load insulin levels, but not
with sVCAM−1. In contrast, the Hoorn study did show an associa−
tion of sVCAM−1 with glucose tolerance status in a population
that also included diabetic individuals [48]. Somewhat smaller
studies including non−diabetic, impaired glucose tolerance and
type 2 diabetic individuals in general demonstrated increased
levels of sVCAM−1, sICAM−1 and sE−selectin in the insulin−resist−
ant state [49 ± 51], although one study observed no association at
all [52]. Studies that included type 2 diabetic individuals only
consistently showed increased levels of sVCAM−1 and sE−selectin
in insulin−resistant individuals; however, the results on sICAM−1
remain inconclusive [28, 53].
In conclusion, there is a trend among studies that shows in−
creased levels of all three endothelial cell adhesion molecules in
insulin resistant states whether or not glucose tolerance is nor−
mal or type 2 diabetes is present.
Type 2 diabetes
Numerous studies have investigated the association between en−
dothelial cell adhesion molecules and type 2 diabetes. As in the
previous sections, conflicting results have been reported. One of
the earliest reports showed increased levels of sVCAM−1 and sE−
selectin with no difference in sICAM−1 levels in type 2 diabetic
individuals compared to controls [54]. Many other findings have
been reported; an increase in sICAM−1 with no change in
sVCAM−1 and sE−selectin [55], and increase in sVCAM−1 and
sICAM−1 with no change in sE−selectin [56], no change in any of
the cellular adhesion molecules [52,57], or an increase in all
three cellular adhesion molecules [50, 58,59]. However, the ma−
jority of the studies show increased levels of endothelial cell ad−
hesion molecules in type 2 diabetic compared to non−diabetic in−
dividuals. In addition, the larger studies, including over 100 type
2 diabetic patients, consistently show that levels of sVCAM−1,
sICAM−1 and sE−selectin are elevated compared to non−diabetic
controls [59 ± 61].
Other studies have investigated whether the presence of diabetic
complications was associated with cellular adhesion molecules.
With regard to nephropathy, Schmidt et al. [62] were among the
first to report increased sVCAM−1 levels in diabetic patients with
microalbuminuria. Others followed by demonstrating increased
sVCAM−1 and/or sICAM−1 levels in the presence of nephropathy
[57, 63], while Lim et al. [64] could not demonstrate any increase
in sVCAM−1 and sICAM−1 levels in diabetic individuals with mi−
croalbuminuria compared to those with normoalbuminuria. In
addition to these cross−sectional studies, the Hoorn study dem−
onstrated that the development of elevated urinary albumin ex−
cretion rate during a follow−up of 6.1 years was significantly
associated with levels of sVCAM−1. [65] Apart from that, Ste−
houwer and colleagues reported sVCAM−1 and sE−selectin to be
interrelated to increased urinary albumin excretion in type 2 dia−
betes during a nine−year follow−up. [66] These two longitudinal
studies provide strong evidence that endothelial dysfunction is
involved in the early development of nephropathy.
Results are more in agreement with regard to retinopathy; Japa−
nese type 2 diabetic individuals with proliferative retinopathy
showed a significant increase in sVCAM−1 compared to those
without proliferative retinopathy [67]. This observation was con−
firmed in diabetic patients with retinopathy but without macro−
vascular disease [53]. The latter study also investigated sE−selec−
tin levels and found similar results, increased levels in the pres−
ence of retinopathy.
Levels of sVCAM−1 and sE−selectin were either increased [53] or
remained similar in type 2 diabetes [64]. The Hoorn study
provided longitudinal data on this subject, as increased sVCAM−
1 levels were significantly associated with increased risk of car−
diovascular mortality (relative risk and [95% confidence interval]
were 1.10 [1.05 ± 1.15] per 100 mg/l increase in sVACM−1) [48].
Taken together, these results suggest that levels of cellular adhe−
sion molecules are increased in type 2 diabetes compared to lev−
els in non−diabetic individuals. With regard to micro− and mac−
rovascular complications, the indications are that cellular adhe−
sion molecules increase in the presence of retinopathy, nephro−
pathy and cardiovascular disease. Longitudinal studies suggest a
pathophysiological role of endothelial function in the develop−
ment of nephropathy and cardiovascular disease.
Prognostic Information from Cellular Adhesion Molecules
Type 2 diabetes
Only little information is available on the prognostic value of cel−
lular adhesion molecules in the development of type 2 diabetes.
Very recently, this issue was investigated in the Nurses’ Health
Study [68], which included 737 incident cases of type 2 diabetes
and 785 age− and race−matched controls followed up for 10 years.
These investigators found that elevated sE−selectin and sICAM−1
levels predicted incident type 2 diabetes in these women, inde−
pendently of known risk factors. Relative risks of diabetes were
7.5 (5.1± 11.1) for sE−selectin and 4.3 (3.0± 6.2) for sICAM−1 in the
highest quintile relative to the lowest quintile of cellular adhesion
molecule levels. The association between sVCAM−1 and incident
diabetes was not independent of known diabetes risk factors.
These results suggest a causal relationship between microvascu−
lar dysfunction and insulin resistance as previously implied [69].
This hypothesis is supported by the findings of the ARIC study,
which has demonstrated that retinal microangiopathy predicts
the development of type 2 diabetes [70].

































Cardiovascular disease in type 2 diabetes
Somewhat more information is available on the prognostic value
of cellular adhesion molecules in relation to cardiovascular dis−
ease in type 2 diabetic individuals. For instance, the Hoorn Study
reported that type 2 diabetic individuals with high sVCAM−1 and
sICAM−1 levels are at increased risk of cardiovascular death
[48,61]. The relative risks for cardiovascular mortality in type 2
diabetic individuals were similar to those in non−diabetic indi−
viduals. However, a much larger population would probably be
necessary to provide evidence of any interaction between dia−
betes and adhesion molecule levels in this relationship. In addi−
tion, a 10−year follow−up study on type 2 diabetic individuals re−
ported associations between sVCAM−1 and sE−selectin and all−
cause mortality [66].
In summary, only few studies have investigated the prognostic
value of cellular adhesion molecules in individuals with charac−
teristics of the metabolic syndrome or diabetes. Importantly, the
one study that did investigate the role of cellular adhesion mol−
ecules in the development of type 2 diabetes showed a markedly
high relative risk, suggesting that endothelial dysfunction is in−
deed an important pathophysiological pathway leading to type
2 diabetes. However, these results would need to be extended
and confirmed by others before drawing any final conclusions.
Conclusions
Cellular adhesion molecules may play an important role in the
development of the metabolic syndrome and type 2 diabetes, as
well as in their cardiovascular complications. All three cellular
adhesion molecules, sVCAM−1, sICAM−1 and sE−selectin, are fre−
quently investigated to improve our knowledge on endothelial
function. The endothelium is thought to be the major source of
the soluble forms of these molecules. Strong evidence exists
that increased levels reflect an alteration of endothelial function,
which may have pathophysiological consequences on the char−
acteristics of the metabolic syndrome and type 2 diabetes. The
strongest evidence is provided by longitudinal studies that
show an association between cellular adhesion molecules and
development of type 2 diabetes and its cardiovascular complica−
tions. Taken together, these results support the concept that en−
dothelial dysfunction is an important pathway leading to type 2
diabetes and cardiovascular disease.
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